Insmed (INSM)
NASDAQ:INSM

Insmed Stock Price & Analysis

385 Followers

INSM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$16.41 - $29.02
Previous Close$20.37
Volume1.33M
Average Volume (3M)1.39M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$513.29M
Total Debt (Recent Filing)$829.77M
Price to Earnings (P/E)-5.6
Beta0.50
Next EarningsFeb 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-3.63
Shares Outstanding135,476,809
R-Squared0.19
Standard Deviation0.19
10 Day Avg. Volume1,293,184
30 Day Avg. Volume1,388,226
Price to Book (P/B)-10.97
Price to Sales (P/S)11.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside114.92% Upside
Rating ConsensusStrong Buy
Alpha-0.00617
Number of Analyst Covering9


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

INSM FAQ

What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $16.41 and its highest was $29.02 in the past 12 months.
    What is Insmed’s market cap?
    Currently, no data Available
    When is Insmed’s upcoming earnings report date?
    Insmed’s upcoming earnings report date is Feb 23, 2023 which is in 80 days.
      How were Insmed’s earnings last quarter?
      Insmed released its earnings results on Oct 27, 2022. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.879 by -$0.211.
        Is Insmed overvalued?
        According to Wall Street analysts Insmed’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Insmed pay dividends?
          Insmed does not currently pay dividends.
          What is Insmed’s EPS estimate?
          Insmed’s EPS estimate is -$0.99.
            How many shares outstanding does Insmed have?
            Insmed has 135,476,800 shares outstanding.
              What happened to Insmed’s price movement after its last earnings report?
              Insmed reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.879. Following the earnings report the stock price went down -4.122%.
                Which hedge fund is a major shareholder of Insmed?
                Among the largest hedge funds holding Insmed’s share is Fairmount Funds Management Llc. It holds Insmed’s shares valued at 29M.

                  ---

                  Insmed Stock Smart Score

                  The Insmed stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Insmed

                  Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Beam Therapeutics
                  PTC Therapeutics
                  Blueprint Medicines
                  IVERIC bio
                  Ultragenyx Pharmaceutical

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis